Skip to main content
. 2020 May;20(3):313–318. doi: 10.7861/clinmed.2019-0250

Table 1.

Characteristics of patients at the first tertiary centre appointment (n=81), stratified by index presentation of chronic liver disease

Decompensated on initial presentation to healthcare, total n=52 Compensated on initial presentation to healthcare, total n=29 p value
Age, years, median (IQR) 59.0 (55.0–62.0) 57.2 (53.0–63.0) 0.752a
Encephalopathy, n (%) 12 (23.1) 10 (34.5) 0.269b
Ascites, n (%) 33 (63.5) 14 (48.3) 0.184b
Varices, n (%) 19 (36.5) 11 (37.9) 0.901b
Hepatocellular carcinoma, n (%) 14 (26.9) 2 (6.9) 0.041c
Ischemic heart disease, n (%) 3 (5.8) 1 (3.4) >0.999c
Vascular disease, n (%) 3 (5.8) 1 (3.4) >0.999c
Diabetes, n (%) 40 (76.9) 27 (93.1) 0.075c
Hypertension, n (%) 20 (38.5) 15 (51.7) 0.248b
Hypercholesterolaemia, n (%) 4 (7.7) 5 (17.2) 0.270c
Platelets, × 109/L, median (IQR) 115.0 (82.0–186.0) 120.0 (65.0–149.0) 0.198a
International normalised ratio, median (IQR) 1.3 (1.1–1.4) 1.4 (1.2–1.5) 0.280a
Sodium, mmol/L, median (IQR) 139.0 (136.0–141.5) 139.5 (137.0–143.5) 0.514a
Creatinine, μmol/L, median (IQR) 84.0 (67.0–118.5) 83.5 (68.5–110.5) 0.766a
Bilirubin, μmol/L, median (IQR) 24.0 (11.0–44.0) 30.0 (11.5–48.0) 0.528a
Alanine aminotransferase, U/L, median (IQR) 35.0 (25.5–44.0) 28.5 (20.0–44.0) 0.106a
Aspartate aminotransferase, U/L, median (IQR) 46.0 (31.0–59.5) 46.0 (35.5–58.0) 0.562a
Fibrosis-4 score, mean±SD 4.37±3.17 5.60±3.03 0.099d
Non-alcoholic fatty liver disease fibrosis score, mean±SD 1.637±1.657 2.371±1.370 0.057d
UK Model for End-Stage Liver Disease score, mean±SD 52.4±5.6 53.4±6.1 0.443d
Model for End-Stage Liver Disease score, median (IQR) 13.0 (10.0–17.0) 16.0 (11.5–18.0) 0.111a

a = continuous data analysed using Mann–Whitney U test;

b = categorical data analysed using Pearson's χ2;

c = categorical data analysed using Fisher's exact test;·

d = continuous data analysed using an independent t-test; IQR = interquartile range; SD = standard deviation.